본문으로 건너뛰기
← 뒤로

Early Driver, Late Bystander: Stage-Specific Roles of DNMT3A R882 Mutations Unveiled in Human AML.

Cancer discovery 2026 Vol.16(3) p. 428-430

Zhou Y, Huang Y

📝 환자 설명용 한 줄

In this issue, Köhnke, Karigane, and colleagues applied allele-specific CRISPR/Cas9 correction in human acute myeloid leukemia samples to dissect the stage-specific functions of DNA methyltransferase

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Zhou Y, Huang Y (2026). Early Driver, Late Bystander: Stage-Specific Roles of DNMT3A R882 Mutations Unveiled in Human AML.. Cancer discovery, 16(3), 428-430. https://doi.org/10.1158/2159-8290.CD-25-2277
MLA Zhou Y, et al.. "Early Driver, Late Bystander: Stage-Specific Roles of DNMT3A R882 Mutations Unveiled in Human AML.." Cancer discovery, vol. 16, no. 3, 2026, pp. 428-430.
PMID 41766430

Abstract

In this issue, Köhnke, Karigane, and colleagues applied allele-specific CRISPR/Cas9 correction in human acute myeloid leukemia samples to dissect the stage-specific functions of DNA methyltransferase 3A (DNMT3A) arginine 882 (R882) mutations. They demonstrate that DNMT3A R882 mutations are required to sustain self-renewal and inflammatory programs in preleukemic cells but become largely dispensable once leukemia is established, while still influencing leukemia stem cell frequency, thereby providing a strong preclinical rationale to reconsider the therapeutic window for targeting DNMT3A-mutant clones early in leukemogenesis. See related article by Köhnke et al., p. 592.

MeSH Terms

Humans; DNA Methyltransferase 3A; Leukemia, Myeloid, Acute; DNA (Cytosine-5-)-Methyltransferases; Mutation

같은 제1저자의 인용 많은 논문 (5)